Across TCGA pan-cancer cohorts, LAMA2 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated LAMA2 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher LAMA2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LAMA2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SARC show a favorable association.
KIRP, KIRC, and UCEC are the cancer types where LAMA2 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.